This Week in Gastroenterology — Oct 27, 2026
Generated Oct 28, 2026 · 11:18
The week's practice-changing Gastroenterology research, summarized for clinicians.
If the audio fails to play, refresh the page to renew the link.
Get next week’s Gastroenterology briefing — free.
In your podcast app, or readable in your inbox with the audio one tap away.
Acetic acid chromoendoscopy for detection of neoplastic Barrett's oesophagus: stepped wedge cluster randomised controlled trial (ACID-trial).
Acetic acid chromoendoscopy did not increase neoplasia detection during community Barrett's surveillance, about 7 percent in both arms, despite doubling the rate of suspected lesions.
BMJ · 2026 · PubMed
This week’s papers
- 01
AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis.
Joint AGA and AASLD guidance issues six PBC recommendations, including ursodeoxycholic acid first line, PPAR agonists for inadequate response, and linerixibat for pruritus, with moderate to very low certainty.
Levy C, Mayo MJ, Carey EJ, et al. · Gastroenterology · 2026
From the briefingIn Gastroenterology, Levy and colleagues present the joint AGA and AASLD clinical practice guideline, built on systematic reviews of six prioritized questions using the GRADE framework [1]. The panel issued six recommendations. They support PBC-specific antinuclear antibodies when antimitochondrial antibodies are negative, ursodeoxycholic acid as first-line therapy, liver stiffness measurement for prognosis, peroxisome proliferator-activated receptor agonists for patients with an inadequate response to or intolerance of ursodeoxycholic acid, linerixibat for moderate to severe pruritus, and ursodeoxycholic acid prophylaxis after transplantation to reduce recurrence. The certainty of evidence ranged from moderate to very low, so several of these rest on thin data.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 02
A phase 2b/3 trial of saroglitazar in primary biliary cholangitis.
Saroglitazar achieved biochemical response in about 57 percent of PBC patients versus about 10 percent on placebo over 52 weeks, though itch benefit was not sustained.
Vuppalanchi R, Villamil A, Yilmaz Y, et al. · Hepatology · 2026
From the briefingThat PPAR agonist recommendation gets fresh support from Hepatology, where Vuppalanchi and colleagues report the EPICS-III phase 2b/3 trial of saroglitazar, a dual PPAR alpha and gamma agonist [2]. In the phase 3 portion, 148 patients with inadequate response or intolerance to ursodeoxycholic acid were randomized for 52 weeks. Just over half of patients on saroglitazar achieved biochemical response, compared with roughly one in ten on placebo. Among patients with less elevated baseline alkaline phosphatase, response climbed to about four in five. Normalization of alkaline phosphatase was uncommon, at about eight percent, though no placebo patient reached it. An early itch benefit at week 24 was not maintained at week 52, and serious adverse events were actually less frequent than on placebo. The endpoints are biochemical rather than clinical outcomes, and the saroglitazar group started with higher liver tests, but this adds another candidate to the second-line class the guideline now endorses.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 03
Prevalence and outcomes of acute presentations of autoimmune hepatitis: Systematic Review and Meta-Analysis.
About 39 percent of autoimmune hepatitis cases present acutely; 90-day transplant-free survival was 79 percent for acute severe disease but only 19 percent with acute liver failure.
Taneja S, Aravind N, Mehtani R, et al. · Clinical Gastroenterology and Hepatology · 2026
From the briefingIn Clinical Gastroenterology and Hepatology, Taneja and colleagues pooled observational studies on acute presentations of autoimmune hepatitis [3]. Across studies that reported both a total cohort and an acute subgroup, close to two in five patients with autoimmune hepatitis presented acutely, although heterogeneity was very high. The phenotypes diverged sharply. Roughly four in five patients with acute severe autoimmune hepatitis were alive without transplant at 90 days, whereas fewer than one in five patients with autoimmune hepatitis–associated acute liver failure were. The authors read this as evidence that most acute presentations do well with timely therapy, while progression to liver failure carries a poor outlook, though the underlying data are observational and inconsistent.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 04
Trends in the etiologies and outcomes of idiosyncratic drug-induced liver injury in the united states: The DILIN prospective registry, 2004 to 2024.
Across two decades of registry data, antibiotic-related liver injury declined proportionally while herbal supplement and antineoplastic cases rose, and oncology patients had about 30 percent six-month mortality.
Fontana RJ, Chalasani N, Hayashi PH, et al. · Hepatology · 2026
From the briefingDrug-induced liver injury is the other great mimic, and in Hepatology, Fontana and colleagues report twenty years of the United States Drug-Induced Liver Injury Network prospective registry, covering nearly two thousand high-causality cases [4]. Antibiotics remained the leading drug class overall, but the share attributed to antimicrobials such as isoniazid and nitrofurantoin fell over time, while the share attributed to herbal and dietary supplements and to antineoplastic agents, including checkpoint inhibitors, rose. Severity markers declined over the two decades. Patients with pre-existing chronic liver disease had higher mortality, and oncology patients had a six-month mortality of about 30 percent, mostly from causes other than the liver.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 05
Baveno VI criteria validation and development of a new non-invasive strategy for varices rule-out in patients with HCC (SAPHE-R: Stiffness, ALBI, Platelets, HEpatocellular carcinoma Rule).
Baveno VI missed about 8.5 percent of varices in hepatocellular carcinoma, whereas the SAPHE-R rule missed under 5 percent in validation but spared fewer endoscopies.
Argiento L, Canova L, Alimenti E, et al. · Hepatology · 2026
From the briefingRounding out this theme, Argiento and colleagues, also in Hepatology, tested whether the Baveno VI criteria can safely spare endoscopy in patients with hepatocellular carcinoma and compensated advanced chronic liver disease [5]. In an Italian cohort of about six hundred patients, Baveno VI missed around eight percent of varices and six percent of high-risk varices. The authors derived an alternative rule, SAPHE-R, combining liver stiffness of 16 kilopascals or less, platelets of at least 160 thousand, and ALBI grade 1. It missed about four percent of varices in derivation and about five percent in an external Vienna cohort, at the cost of sparing fewer endoscopies, roughly one in six rather than nearly one in three. That trade of safety for efficiency is worth weighing, and the rule still needs prospective testing before it could change surveillance pathways.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 06
Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI.
Intravenous and subcutaneous guselkumab induction showed no statistical efficacy difference in Crohn's disease, with deep remission in roughly 40 to 51 percent at week 96 either way.
D'Haens GR, Afzali A, Danese S, et al. · Clinical Gastroenterology and Hepatology · 2026
From the briefingIn Clinical Gastroenterology and Hepatology, D'Haens and colleagues compared intravenous and subcutaneous guselkumab induction in moderately to severely active Crohn's disease, drawing on the GALAXI and GRAVITI programs [6]. A weighted cross-trial analysis found no statistical difference between the two routes, both were clearly superior to placebo at week 12, and clinical response and remission appeared by week 4 with either route. The similarity held across subgroups, including patients with high baseline disease activity, and by week 96 somewhere between about two in five and half of patients on guselkumab reached deep remission regardless of how they were induced. These are indirect comparisons across separate trials, sponsored data, but they support subcutaneous induction as a credible alternative to infusion.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 07
TASTY AND HEALTHY DIET REDUCES FECAL CALPROTECTIN IN HIGH-RISK FIRST-DEGREE RELATIVES OF PATIENTS WITH CROHN'S DISEASE: PIONIR RANDOMIZED CROSSOVER TRIAL.
In 29 at-risk relatives of Crohn's patients, an eight-week Tasty and Healthy diet halved calprotectin in 71 percent versus 27 percent on habitual diet, supporting prevention trials.
Turner D, Kenigsberg S, Plotkin L, et al. · Gastroenterology · 2026
From the briefingAt the other end of the disease spectrum, Turner and colleagues report the PIONIR trial in Gastroenterology [7]. Twenty-nine first-degree relatives of patients with Crohn's disease, all with persistently elevated faecal calprotectin but no diagnostic endoscopic disease, were randomized in a crossover design to the Tasty and Healthy diet or their habitual diet. About seven in ten participants on the diet halved their calprotectin, versus about a quarter on habitual diet, and acceptability and adherence were high. This is a small, short study with a surrogate marker, not a demonstration that disease onset can be prevented, but it shows that low-grade inflammation in at-risk relatives is modifiable and lays the groundwork for longer prevention trials.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 08
Acetic acid chromoendoscopy for detection of neoplastic Barrett's oesophagus: stepped wedge cluster randomised controlled trial (ACID-trial).
Acetic acid chromoendoscopy did not increase neoplasia detection during community Barrett's surveillance, about 7 percent in both arms, despite doubling the rate of suspected lesions.
Beaufort IN, Boer LS, Milne AN, et al. · BMJ · 2026
From the briefingIn the BMJ, Beaufort and colleagues ran the ACID trial, a stepped wedge cluster randomized study across 18 Dutch community hospitals testing acetic acid chromoendoscopy during Barrett's oesophagus surveillance [8]. Among more than two thousand patients without prior dysplasia, acetic acid did not increase neoplasia detection, which sat around seven percent in both arms. Endoscopists flagged suspicious lesions more than twice as often with acetic acid, but targeted biopsies yielded no more neoplasia. The setting was routine community practice, which is exactly where the technique was hoped to help, and the result does not support adding it to standard surveillance there.
If you only have time for one paper this week, make it the ACID trial in the BMJ [8]. It is a large, practice-embedded randomized trial that settles a question many surveillance programs had left open, showing that a cheap and widely promoted adjunct generates more suspicious findings without finding more neoplasia.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 09
Helicobacter pylori Infection - Advances, Challenges, and the Road Ahead.
A review of four decades of Helicobacter pylori research highlights gastric cancer prevention through screening while identifying absent vaccines and rising antibiotic resistance as the key unresolved barriers.
Li H, Megraud F, Marshall BJ · New England Journal of Medicine · 2026
From the briefingIn the New England Journal of Medicine, Li, Megraud, and Marshall review four decades of Helicobacter pylori research [9], covering pathogenesis, global burden, screening for gastric cancer prevention, and emerging management trends, while stressing that the absence of a vaccine and rising antibiotic resistance remain the central obstacles.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 10
14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.
A 14-day trifluridine-tipiracil plus bevacizumab schedule was non-inferior for survival in refractory metastatic colorectal cancer while cutting grade 3 neutropenia from 39 to 13 percent.
Sakakida T, Taniguchi H, Asayama M, et al. · The Lancet · 2026
From the briefingAnd in The Lancet, Sakakida and colleagues report PRABITAS, a pragmatic phase 3 non-inferiority trial in 178 Japanese hospitals comparing a simplified 14-day schedule of trifluridine-tipiracil plus bevacizumab against the conventional 28-day schedule in refractory metastatic colorectal cancer [10]. Among 970 patients, the 14-day schedule met non-inferiority for overall survival, with median survival of about eleven months versus about ten. Severe neutropenia fell to roughly a third of its conventional rate, and anorexia also decreased, although there were two treatment-related deaths in the 14-day arm and none in the 28-day arm. The authors argue the simplified schedule should become the new standard, a conclusion drawn from a single open-label trial in one country.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
The full briefing
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Gastroenterology. This week we're covering 10 notable papers spanning autoimmune and cholestatic liver disease, the evolving landscape of liver injury and portal hypertension, inflammatory bowel disease from prevention to biologic induction, and a set of results in endoscopy and gastrointestinal oncology. Let's dive in.
We start with primary biliary cholangitis, where a major guideline and a pivotal trial both point toward earlier, risk-based escalation of therapy. In Gastroenterology, Levy and colleagues present the joint AGA and AASLD clinical practice guideline, built on systematic reviews of six prioritized questions using the GRADE framework [1]. The panel issued six recommendations. They support PBC-specific antinuclear antibodies when antimitochondrial antibodies are negative, ursodeoxycholic acid as first-line therapy, liver stiffness measurement for prognosis, peroxisome proliferator-activated receptor agonists for patients with an inadequate response to or intolerance of ursodeoxycholic acid, linerixibat for moderate to severe pruritus, and ursodeoxycholic acid prophylaxis after transplantation to reduce recurrence. The certainty of evidence ranged from moderate to very low, so several of these rest on thin data. That PPAR agonist recommendation gets fresh support from Hepatology, where Vuppalanchi and colleagues report the EPICS-III phase 2b/3 trial of saroglitazar, a dual PPAR alpha and gamma agonist [2]. In the phase 3 portion, 148 patients with inadequate response or intolerance to ursodeoxycholic acid were randomized for 52 weeks. Just over half of patients on saroglitazar achieved biochemical response, compared with roughly one in ten on placebo. Among patients with less elevated baseline alkaline phosphatase, response climbed to about four in five. Normalization of alkaline phosphatase was uncommon, at about eight percent, though no placebo patient reached it. An early itch benefit at week 24 was not maintained at week 52, and serious adverse events were actually less frequent than on placebo. The endpoints are biochemical rather than clinical outcomes, and the saroglitazar group started with higher liver tests, but this adds another candidate to the second-line class the guideline now endorses.
Staying in the liver, three papers sharpen how we recognize and risk-stratify acute and progressive liver disease. In Clinical Gastroenterology and Hepatology, Taneja and colleagues pooled observational studies on acute presentations of autoimmune hepatitis [3]. Across studies that reported both a total cohort and an acute subgroup, close to two in five patients with autoimmune hepatitis presented acutely, although heterogeneity was very high. The phenotypes diverged sharply. Roughly four in five patients with acute severe autoimmune hepatitis were alive without transplant at 90 days, whereas fewer than one in five patients with autoimmune hepatitis–associated acute liver failure were. The authors read this as evidence that most acute presentations do well with timely therapy, while progression to liver failure carries a poor outlook, though the underlying data are observational and inconsistent. Drug-induced liver injury is the other great mimic, and in Hepatology, Fontana and colleagues report twenty years of the United States Drug-Induced Liver Injury Network prospective registry, covering nearly two thousand high-causality cases [4]. Antibiotics remained the leading drug class overall, but the share attributed to antimicrobials such as isoniazid and nitrofurantoin fell over time, while the share attributed to herbal and dietary supplements and to antineoplastic agents, including checkpoint inhibitors, rose. Severity markers declined over the two decades. Patients with pre-existing chronic liver disease had higher mortality, and oncology patients had a six-month mortality of about 30 percent, mostly from causes other than the liver. Rounding out this theme, Argiento and colleagues, also in Hepatology, tested whether the Baveno VI criteria can safely spare endoscopy in patients with hepatocellular carcinoma and compensated advanced chronic liver disease [5]. In an Italian cohort of about six hundred patients, Baveno VI missed around eight percent of varices and six percent of high-risk varices. The authors derived an alternative rule, SAPHE-R, combining liver stiffness of 16 kilopascals or less, platelets of at least 160 thousand, and ALBI grade 1. It missed about four percent of varices in derivation and about five percent in an external Vienna cohort, at the cost of sparing fewer endoscopies, roughly one in six rather than nearly one in three. That trade of safety for efficiency is worth weighing, and the rule still needs prospective testing before it could change surveillance pathways.
Turning to inflammatory bowel disease, this week's papers span the earliest stage of disease to established Crohn's treatment. In Clinical Gastroenterology and Hepatology, D'Haens and colleagues compared intravenous and subcutaneous guselkumab induction in moderately to severely active Crohn's disease, drawing on the GALAXI and GRAVITI programs [6]. A weighted cross-trial analysis found no statistical difference between the two routes, both were clearly superior to placebo at week 12, and clinical response and remission appeared by week 4 with either route. The similarity held across subgroups, including patients with high baseline disease activity, and by week 96 somewhere between about two in five and half of patients on guselkumab reached deep remission regardless of how they were induced. These are indirect comparisons across separate trials, sponsored data, but they support subcutaneous induction as a credible alternative to infusion. At the other end of the disease spectrum, Turner and colleagues report the PIONIR trial in Gastroenterology [7]. Twenty-nine first-degree relatives of patients with Crohn's disease, all with persistently elevated faecal calprotectin but no diagnostic endoscopic disease, were randomized in a crossover design to the Tasty and Healthy diet or their habitual diet. About seven in ten participants on the diet halved their calprotectin, versus about a quarter on habitual diet, and acceptability and adherence were high. This is a small, short study with a surrogate marker, not a demonstration that disease onset can be prevented, but it shows that low-grade inflammation in at-risk relatives is modifiable and lays the groundwork for longer prevention trials.
Our final theme covers endoscopy, gastric infection, and gastrointestinal cancer, led by a cleanly negative trial. In the BMJ, Beaufort and colleagues ran the ACID trial, a stepped wedge cluster randomized study across 18 Dutch community hospitals testing acetic acid chromoendoscopy during Barrett's oesophagus surveillance [8]. Among more than two thousand patients without prior dysplasia, acetic acid did not increase neoplasia detection, which sat around seven percent in both arms. Endoscopists flagged suspicious lesions more than twice as often with acetic acid, but targeted biopsies yielded no more neoplasia. The setting was routine community practice, which is exactly where the technique was hoped to help, and the result does not support adding it to standard surveillance there. In the New England Journal of Medicine, Li, Megraud, and Marshall review four decades of Helicobacter pylori research [9], covering pathogenesis, global burden, screening for gastric cancer prevention, and emerging management trends, while stressing that the absence of a vaccine and rising antibiotic resistance remain the central obstacles. And in The Lancet, Sakakida and colleagues report PRABITAS, a pragmatic phase 3 non-inferiority trial in 178 Japanese hospitals comparing a simplified 14-day schedule of trifluridine-tipiracil plus bevacizumab against the conventional 28-day schedule in refractory metastatic colorectal cancer [10]. Among 970 patients, the 14-day schedule met non-inferiority for overall survival, with median survival of about eleven months versus about ten. Severe neutropenia fell to roughly a third of its conventional rate, and anorexia also decreased, although there were two treatment-related deaths in the 14-day arm and none in the 28-day arm. The authors argue the simplified schedule should become the new standard, a conclusion drawn from a single open-label trial in one country.
If you only have time for one paper this week, make it the ACID trial in the BMJ [8]. It is a large, practice-embedded randomized trial that settles a question many surveillance programs had left open, showing that a cheap and widely promoted adjunct generates more suspicious findings without finding more neoplasia.
Here is what this week's evidence adds up to in Gastroenterology. First, primary biliary cholangitis now has a formal North American framework for risk-based escalation, and saroglitazar adds trial evidence for another PPAR agonist, though outcomes remain biochemical and guideline certainty is often low. Second, acute autoimmune hepatitis is common and heterogeneous, and the registry data show drug-induced liver injury shifting toward supplements and cancer therapies, both from observational sources. Third, Baveno VI appears less reliable in hepatocellular carcinoma, and SAPHE-R is a promising but not yet prospectively validated alternative. Fourth, subcutaneous guselkumab induction looks comparable to intravenous in indirect comparisons, while dietary modulation of inflammation in at-risk relatives remains early, surrogate-level evidence. Fifth, acetic acid chromoendoscopy did not improve Barrett's neoplasia detection in community practice, and a gentler trifluridine-tipiracil schedule preserved survival in a single Japanese trial.
That's your roundup for This Week in Gastroenterology. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if it saves you time, a quick rating in your podcast app helps other physicians find the show.
This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.
Spot something worth flagging?
Get this every week in your podcast app — free.
New gastroenterology episodes land in your feed automatically — listen on your commute.